Adversity, Adaption, Delivery, Expansion: How One CDMO Navigated The Pandemic
The COVID-19 pandemic has changed pharma for good. Though we are now well past the two-year mark, the impact of the ordeal has changed the ways companies “think” and function. Despite the rapid transformations thrust upon the sector, companies have shown a commendable level of dedication to their shared goal of improving patient lives. Many companies ran at full speed for every single second of the pandemic’s “unforgiving minute.”
PCI Pharma Services is one such company. We asked some of PCI’s leaders to meet around the table to discuss the critical moves they made during this testing time and the choices that ensured the company’s growth in key areas, including sterile fill-finish and lyophilization capacity to support the increasing demand for end-to-end integrated solutions from development through to commercialization.
The PCI leaders featured in this Q&A are:
Tom McGrath
VP, Global Quality for Manufacturing & Development, PCI Pharma Services
Aimee Hodge
VP, Technical Services & Validation, PCI Pharma Services
Shawn Cain
Senior VP, Development & Manufacturing, PCI Pharma Services
Jeff Clement
Executive Director, Business Development, North America, PCI Pharma Services
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.